CoChat

Targets of therapy in progressive MS

Open access
Lassmann, Hans · 2017 · Multiple Sclerosis Journal
Cited by 82

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Highly effective anti-inflammatory therapies have so far been developed for patients with relapsing/remitting multiple sclerosis, which also show some benefits in the early progressive stage of the disease. However, treatment options for patients, who have entered the progressive phase, are still limited. Disease starts as an inflammatory process, which induces focal demyelinating lesions in the gray and white matter. This stage of the disease dominates in the relapsing phase, extends into the early stages of progressive disease, and can be targeted by current anti-inflammatory treatments. In parallel, inflammation accumulates behind a closed or repaired blood brain barrier, and this process peaks in the late relapsing and early progressive stage and then declines. Some data suggest that this process may be targeted by immune ablation and hematopoietic stem cell transplantation. In the late stage, inflammation may decline to levels seen in age-matched controls, but age and disease burden–related neurodegeneration ensues. Such neurodegeneration affects the damaged brain and spinal cord, in which functional reserve capacity is exhausted, giving rise to further disability progression. Anti-inflammatory treatments are unlikely to be beneficial in this stage of the disease, but neuroprotective and repair-inducing strategies may still be effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1352458517729455

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 82

Metadata

Authors
Lassmann, H.
Venue
Multiple Sclerosis Journal
Published
2017-10
Volume
23
Issue
12
Pages
1593-1599
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2767151013
Cited by
82
References
24
FWCI
5.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targets of therapy in progressive MS. https://app.cochat.ai/papers/10.1177/1352458517729455
The paper
Lassmann, H. (2017). Targets of therapy in progressive MS. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458517729455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.